The announcement recently about re-applying for the Rolling

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps havasu78 #88911
519
The announcement recently about re-applying for the Rolling Review for the HIV BLA because it expired has some bearing on this filing.

Last time we filed for BLA we had the possibility of the Rolling Review but didn’t take advantage of that direction of reviewing each part of the BLA in a section by section review as it was completed. We just filed the whole BLA at one time and had previously only filed the manufacturing section for review previous to the rest.

My understanding is we could of filed section by section and sought guidance as we went along. Being a fledgling biotech you would think that would of been the way of choice. To have the FDA evaluate each section as it is completed and correct those that are not properly formatted or missing the needed information.

I think Amerex had some bearing on completing the BLA and thought it was proper enough to file it all at one time. That didn’t work out and the advantage of rolling review wasn’t really used as it could of been.

The relationship between Amerex and Cytodyn didn’t suffer for this set back and we continue to use Amerex for our trial performance and oversight. Yet the new Merck employee specializes in Trials oversight amongst many skills this employee has. What does this say? The old saying... fool me once and shame on you. Fool me twice and shame on me. Comes to mind. My hope is we won’t be fooled again to believe we have this completed when it’s not approvable.

There were only two parts of the BLA we needed to correct and now we have apparently corrected those two parts or are very close to completing those corrections.

Does rolling review mean that we can submit those corrected issues for review without full filing and have the blessing of the correction first before completing the whole BLA submission? I am not completely sure on what flexibility is given to rolling review but it seems likely that is the way a rolling review should work. Perhaps someone has the knowledge of section by section rolling review and if we need to file again by section or just complete the corrections to the sections we didn’t meet the grade? The filing could be very quick with just a couple corrections for rolling review and then submit the whole BLA right after we complete that correction review.

I want to believe it is that easy. That we can ask for corrections to be reviewed before seeking approval for the whole BLA to avoid another Refusal to File Letter. Another RFL would be devastating. So rolling review might be the action of choice if it works for seeking correction advice before complete submission for approval. Let’s hope that is the way it works because we had a completed BLA with two problems already now corrected or at least by July they will be completely corrected.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 34

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 36

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 38

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 62

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 47

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 45

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Mixed Markets: Analyzing Germany's Stock Performance

Updated Category News Views 211

Markets in Germany Prepare for Fluctuations As trading wrapped up on Wednesday, the German stock market exhibited a mixed bag of results. While certain sectors, such as Food & Beverages, Media, and Financial Services, reported gains, others faced setbacks. The Consumer & Cyclical, Construction, and Pharmaceuticals & Healthcare sectors saw declines, reflecting the market's...

Continue Reading
Teradyne's Q3 Earnings: Strong Performance and Future Growth Potential

Updated Category News Views 176

Teradyne's Q3 Earnings Exceed Expectations Teradyne Incorporated (NASDAQ: TER), a prominent player in automated test equipment, has released its third-quarter results, building a narrative of success and optimism. The company reported impressive sales figures of $737 million, with non-GAAP earnings per share (EPS) reaching $0.90, bolstered by a solid gross margin of...

Continue Reading
So-Young Plans to Revise ADS Ratio for Improved Trading

Updated Category News Views 163

So-Young's Strategic Shift in ADS Ratio So-Young International Inc. (NASDAQ: SY), a leading aesthetic treatment platform, has recently announced plans to change the ratio of its American depositary shares (ADSs) to Class A ordinary shares. This strategic decision aims to refine its trading dynamics, enhancing value for its shareholders. Details of the ADS Ratio Change The...

Continue Reading
Understanding Recent Developments at GitLab: Investor Insights

Updated Category News Views 78

Contextual Overview of GitLab's Recent Investor Challenges In a rapidly evolving technological landscape, GitLab Inc. stands at a critical juncture as investors navigate its latest developments and challenges. Recent announcements regarding financial performance have sparked interest and concern among stakeholders. Understanding the implications of these changes is...

Continue Reading
Celebrating 15 Years of Transformative Care at Senderra Pharmacy

Updated Category News Views 273

15 Years of Innovation in Specialty Pharmacy Senderra Specialty Pharmacy has proudly reached a remarkable milestone—15 years of providing top-tier healthcare solutions in the specialty pharmacy sector. This anniversary embodies a journey marked by significant advancements and unwavering commitment to revolutionizing patient care. Transforming Patient Experiences Since...

Continue Reading